TLDR
- Novo Nordisk is partnering with Anthropic to use the Claude Science platform to speed up drug discovery and development.
- NVO stock rose 3.55% on the news, with peers Eli Lilly (LLY) and Merck (MRK) also gaining.
- A European Medicines Agency panel has recommended approval of Frehemgo, Novo’s hemophilia A treatment.
- Novo plans to launch Frehemgo in a selected European market in Q4 2026, with a broader EU rollout in early 2027.
- The company has also rebranded, dropping “Nordisk” and will now go by simply “Novo.”
Novo Nordisk stock climbed 3.55% after the Danish drugmaker announced a partnership with Anthropic and received a positive recommendation for its hemophilia drug in Europe.
The deal will see Novo use Anthropic’s Claude Science platform to help shorten drug discovery timelines and improve software development internally. Novo CEO Mike Doustdar said AI can “compress the path from research to marketed product” and open up new scientific opportunities.
Dario Amodei, Anthropic’s co-founder and CEO, said the collaboration is “built to achieve” shorter research timelines and better treatment outcomes. Terms of the deal were not disclosed, and Novo did not specify which drug programs would be targeted.
The Anthropic partnership is not Novo’s first AI move. Earlier this year the company announced it would work with OpenAI and created an AI innovation hub with Amazon Web Services.
Rivals Eli Lilly, Merck, and Roche have all made AI investments of their own. So far, across the industry, the clearest gains from AI have come through automating routine work like analyzing datasets, synthesizing research, and designing clinical trials. No AI-discovered drug has received regulatory approval yet.
Novo has been under pressure. Its stock has fallen around 20% over the past year as competition in the GLP-1 weight-loss drug space has intensified. This week, the company also unveiled a rebrand, dropping “Nordisk” from its name and adopting the simpler “Novo” along with a new logo.
Hemophilia Drug Clears European Hurdle
Adding to the day’s positive news, a European Medicines Agency panel recommended approval of Frehemgo, Novo’s injectable treatment for hemophilia A.
The recommendation covers both adults and children, including patients with or without inhibitors. Clinical trial data from Novo’s FRONTIER program showed Frehemgo reduced annualized bleeding rates compared to existing clotting-factor treatments.
Frehemgo will be sold in a single-use, prefilled pen with dosing options ranging from once weekly to once monthly, giving patients more flexibility than current options.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
